Strides Pharma Family Office

Strides Pharma Family Office operates as the private investment vehicle of Arun Kumar, the founder of Strides Pharma Science Limited, a prominent Indian pharmaceutical company. While distinct from the publicly traded pharmaceutical entity, the family office strategically invests within the broader healthcare and pharmaceutical ecosystem. Its investment activities are closely aligned with fostering growth and innovation in related ventures, often partnering with or supporting companies with ties to the Strides Pharma group.

The family office's origins are intrinsically linked to Arun Kumar's entrepreneurial journey, which began with the establishment of Strides Arcolab Limited (later Strides Pharma Science Limited) in 1990. Over the years, as the pharmaceutical business expanded globally, the family office emerged as a key investor, leveraging Kumar's deep industry expertise and capital to support strategic initiatives and new ventures within the healthcare sector.

Notable investments by Strides Pharma Family Office include the acquisition of a 3.7% stake in Strides Pharma Science Limited from SeQuent Scientific Ltd for approximately $21 million in August 2020. The family office also played a significant role in the Series C funding round for Stelis Biopharma, a division of Strides Pharma Science, in March 2021, which raised $125 million. Furthermore, it partnered with Strides Pharma Science to infuse capital into SteriScience Pharma, a dedicated arm for global sterile injectables, with a total investment of Rs 4,000 million planned until operational break-even.

The firm's investment strategy benefits from the extensive pharmaceutical industry experience of its principals, particularly Arun Kumar, who transitioned to Non-Executive Chairperson of Strides Pharma Science Limited in April 2025. Aditya Arun Kumar, who has held multiple positions in both Strides and the Family Office, serves as the Executive Director – Business Development for Strides Pharma Science, indicating a close operational and strategic synergy between the family office's investments and the broader Strides group's objectives.